Levolet is a drug owned by Genus Life Sciences Inc. It is protected by 2 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 23, 2038. Details of Levolet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10231931 | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(13 years from now) | Active |
| US10406108 | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Levolet's patents.
Latest Legal Activities on Levolet's Patents
Given below is the list of recent legal activities going on the following patents of Levolet.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Mar, 2023 | US10406108 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Sep, 2022 | US10231931 |
| Patent Issue Date Used in PTA Calculation Critical | 10 Sep, 2019 | US10406108 |
| Application ready for PDX access by participating foreign offices Critical | 10 Sep, 2019 | US10406108 |
| Recordation of Patent Grant Mailed Critical | 10 Sep, 2019 | US10406108 |
| Email Notification Critical | 22 Aug, 2019 | US10406108 |
| Issue Notification Mailed Critical | 21 Aug, 2019 | US10406108 |
| Dispatch to FDC | 07 Aug, 2019 | US10406108 |
| Application Is Considered Ready for Issue Critical | 01 Aug, 2019 | US10406108 |
| Issue Fee Payment Received Critical | 26 Jul, 2019 | US10406108 |
US patents provide insights into the exclusivity only within the United States, but Levolet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Levolet's family patents as well as insights into ongoing legal events on those patents.
Levolet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Levolet's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 23, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Levolet Generic API suppliers:
Levothyroxine Sodium is the generic name for the brand Levolet. 16 different companies have already filed for the generic of Levolet, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Levolet's generic
Alternative Brands for Levolet
There are several other brand drugs using the same active ingredient (Levothyroxine Sodium) as Levolet. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Azurity |
| ||
| Cediprof Inc |
| ||
| Fresenius Kabi Usa |
| ||
| Hikma |
| ||
| Ibsa |
| ||
| Inst Biochimique |
| ||
| King Pharms |
| ||
| Mylan |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Levothyroxine Sodium, Levolet's active ingredient. Check the complete list of approved generic manufacturers for Levolet
About Levolet
Levolet is a drug owned by Genus Life Sciences Inc. Levolet uses Levothyroxine Sodium as an active ingredient. Levolet was launched by Genus Lifesciences in 2003.
Approval Date:
Levolet was approved by FDA for market use on 06 June, 2003.
Active Ingredient:
Levolet uses Levothyroxine Sodium as the active ingredient. Check out other Drugs and Companies using Levothyroxine Sodium ingredient
Dosage:
Levolet is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |